HIMS

FDA staff challenged seven compounded peptides, but Hims & Hers continues expanding internationally and strengthening its core healthcare platform beyond longevity therapies. The $400 million JPMorgan receivables facility improves financial flexibility, supporting GLP-1 expansion without relying on dilutive equity financing. The $1.15 billion Eucalyptus acquisition adds 850,000 customers and approximately $450 million of ARR across eight international markets.

Hims & Hers Health continues to drive impressive growth through its subscription-based consumer wellness platform. Teladoc Health maintains a dominant market share with over 100 million global members and significant institutional partnerships.

The healthcare sector is one of the best-performing sectors in the S&P 500 over the past month, with a gain of around 6%. But while that rebound has been led by a handful of mega-cap Big Pharma companies, it has also been reflected in the performances of smaller firms.

The stock rebounded from below $14 after a regulatory shock and is now trading above $37 on a diversified growth narrative. Monthly weight-loss subscriber additions exceed one hundred thousand, transforming GLP-1 products into a powerful customer acquisition funnel. Peptides, AI healthcare systems, and international expansion create multi-layered optionality beyond traditional telehealth and pharmacy models.

The Amplify Online Retail ETF (IBUY) has rallied over the past month, signaling a robust appetite for online consumer discretionary spending despite persistent macroeconomic headwinds. Outsized gains in specialized healthcare retail and online travel names have driven performance for IBUY's underlying index.

Hims & Hers Health shares (HIMS) surged 9% on Wednesday after Canaccord Genuity raised its price target on the telehealth company, citing improving sales trends, momentum in its weight-loss business, and growing optimism around its peptide opportunity. Canaccord analyst Maria Ripps maintained a Buy rating on the stock while increasing her price target to $40 from $32, implying additional upside from current levels.

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?

Telehealth provider Hims and Hers Health may get a boost next year from employers dropping coverage of weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo ​to rein in costs, investors and analysts say.

Blue Owl Capital presents a compelling high-yield opportunity with a nearly 10% dividend, despite investor concerns about its credit business. IBM secures a bullish catalyst as the US government proposes a $1B equity stake to support its quantum computing roadmap. Quantum Computing is a speculative buy, leveraging a strong cash position and accelerating revenue in a nascent market projected at 35% CAGR.